Literature DB >> 3081419

Cardiopulmonary bypass: a low T4 and T3 syndrome with blunted thyrotropin (TSH) response to thyrotropin-releasing hormone (TRH).

G Robuschi, D Medici, F Fesani, G Barboso, M Montermini, L d'Amato, E Gardini, E Borciani, E Dall'Aglio, M Salvi.   

Abstract

Thyroid hormone serum concentrations, the thyrotropin (TSH) and prolactin (PRL) response to thyrotropin-releasing hormone (TRH) were evaluated in patients undergoing cardiopulmonary bypass (CPB) conducted in hypothermia. During CPB a marked decrease of thyroxine (T4) and triiodothyronine (T3) concentration with a concomitant increase of reverse T3 (rT3) were observed similarly to other clinical states associated with the 'low T3 syndrome'. Furthermore, in the present study elevated FT4 and FT3 concentrations were observed. In a group of patients, TRH administered during CPB at 26 degrees C elicited a markedly blunted TSH response. In these patients, PRL concentration was elevated but did not significantly increase after TRH. The increased concentrations of FT4 and FT3 were probably due to the large doses of heparin administered to these patients. Thus, the blunted response of TSH to TRH might be the consequence of the elevation of FT4 and FT3 in serum, however, other factors might play a role since also the PRL response to TRH was blocked.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3081419     DOI: 10.1159/000180311

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  10 in total

1.  Plasma free triiodothyronine (fT3) levels in baboons undergoing pig organ transplantation: relevance to early recovery of organ function.

Authors:  Hayato Iwase; Burcin Ekser; Vikas Satyananda; Mohamed Ezzelarab; David K C Cooper
Journal:  Xenotransplantation       Date:  2014-07-08       Impact factor: 3.907

Review 2.  Overcoming Coagulation Dysregulation in Pig Solid Organ Transplantation in Nonhuman Primates: Recent Progress.

Authors:  Liaoran Wang; David K C Cooper; Lars Burdorf; Yi Wang; Hayato Iwase
Journal:  Transplantation       Date:  2018-07       Impact factor: 4.939

3.  Effect of triiodothyronine administration in experimental myocardial injury.

Authors:  R B Hsu; T S Huang; Y S Chen; S H Chu
Journal:  J Endocrinol Invest       Date:  1995-10       Impact factor: 4.256

4.  Identifying infants at risk of marked thyroid suppression post-cardiopulmonary bypass.

Authors:  Kevin Plumpton; Nikolaus A Haas
Journal:  Intensive Care Med       Date:  2005-01-28       Impact factor: 17.440

Review 5.  Nonthyroidal illness syndrome in children.

Authors:  Seth D Marks
Journal:  Endocrine       Date:  2009-09-25       Impact factor: 3.633

6.  Evaluation of serum total thyroxine and triiodothyronine and their serum fractions in nonthyroidal illness secondary to congenital heart disease. Studies before and after surgery.

Authors:  A Belgorosky; G Weller; E Chaler; S Iorcansky; M A Rivarola
Journal:  J Endocrinol Invest       Date:  1993 Jul-Aug       Impact factor: 4.256

7.  Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats.

Authors:  Yue-Feng Chen; Satoru Kobayashi; Jinghai Chen; Rebecca A Redetzke; Suleman Said; Qiangrong Liang; A Martin Gerdes
Journal:  J Mol Cell Cardiol       Date:  2007-10-26       Impact factor: 5.000

8.  Thyroid hormone: relevance to xenotransplantation.

Authors:  Hayato Iwase; Burcin Ekser; Hidetaka Hara; Mohamed B Ezzelarab; Cassandra Long; Angus W Thomson; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2016-07-04       Impact factor: 3.907

Review 9.  Thyroid hormones and cardiovascular disease.

Authors:  Avais Jabbar; Alessandro Pingitore; Simon H S Pearce; Azfar Zaman; Giorgio Iervasi; Salman Razvi
Journal:  Nat Rev Cardiol       Date:  2016-11-04       Impact factor: 32.419

Review 10.  Evidence for the important role of inflammation in xenotransplantation.

Authors:  Juan Li; Hidetaka Hara; Yi Wang; Charles Esmon; David K C Cooper; Hayato Iwase
Journal:  J Inflamm (Lond)       Date:  2019-05-28       Impact factor: 4.981

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.